12
2009 Annual Membership Meeting July 24 ~ 26, 2009 Hyatt Regency Atlanta 265 Peachtree Street, NE Atlanta, GA 30303 (404) 577-1234
2009 Annual Membership Meeting
July 24 ~ 26, 2009
Hyatt Regency Atlanta
265 Peachtree Street, NE Atlanta, GA 30303
(404) 577-1234
June 5, 2009 Dear GASCO Member: We would like to invite you to participate in a unique opportunity for leading edge clinical education and networking with your colleagues in Georgia and other parts of the country. This year the GASCO Board moved up the date of our Annual Meeting to July 24 – 26, 2009 in order to co-locate our meeting with the East Coast Best of ASCO® (BOA) meeting planned in Atlanta on July 24th and 25th. The meeting will be held at the Hyatt Regency Hotel in Atlanta. GASCO will also be sponsoring a President’s reception on Friday evening and business of oncology educational sessions for our Administrators Association and other interested parties on Saturday, July 25th. We are very proud to also offer a special session on Sunday, July 26th focusing on Promoting Cancer Patient Navigation Services. This program is made possible through an ASCO State Affiliate Grant awarded to GASCO in April (see attached agenda of GASCO sponsored activities). To encourage participation in these important programs, there will be no additional charge to participate in GASCO sponsored activities. Registration for Best of ASCO® We have attached a copy of the BOA agenda for your review and are proud to have GASCO members as part of this year’s faculty. Physicians and clinical staff who wish to attend the Best of ASCO® sessions and require lodging should register directly with ASCO on their website. http://www.asco.org/ASCOv2/Meetings/Best+of+ASCO/Best+of+ASCO+Atlanta ASCO’s early registration discount deadline is 11:59 PM EST, on Monday, June 15, 2009. For help or questions regarding ASCO registration contact: Best of ASCO® Registration Center 11208 Waples Mill Road, Suite 112 Fairfax, VA 22030 Phone:888-788-1522 Fax: 703-818-6425 E-mail:[email protected]
Page 2 Registration for GASCO Sponsored Sessions For Administrative Staff, Patient Navigators and other interested parties, please complete the enclosed registration form for each person attending the GASCO sponsored programs. The GASCO meeting registration deadline is the earlier of Friday, July 17 or until the space is filled. You may register for the meeting online at www.gasco.us , by facsimile (770) 951-2157 or regular mail. Call Kellie Reich at (770) 951-1018 if you need to discuss your registration or if you have problems with our online system. If you require accommodations, please contact the Hyatt Regency, Atlanta at (800) 233 1234 and ask for the ASCO Rate, which is $190 per night plus taxes. On behalf of the members of GASCO, we sincerely thank you for your support of our organization. We look forward to seeing you in Atlanta. Sincerely,
Matthew Mumber, M.D. President Georgia Society of Clinical Oncology Enclosures **The GASCO Annual Meeting is not sponsored by ASCO®. Best of ASCO® is a registered trademark of the American Society of Clinical Oncology®. All rights reserved.
Annual Membership Meeting July 24 ~ -26, 2009
Hyatt Regency Atlanta REGISTRATION FORM - One Form Per Person – Deadline: July 17, 2009 _________________________________________________________________________ Name (as you would like it to appear on name badge including MD, RN, etc.) _________________________________________________________________________ Name of Practice/Organization _________________________________________________________________________ Address _________________________________________________________________________ City State Zip (_____)_________________________________(_____)___________________________ Phone Fax _________________________________________________________________________ E-mail address SPECIAL OFFER TO ONCOLOGY/HEMATOLOGY PHYSICIANS This year since we are co-locating out meeting with the Best of ASCO, there will be no charge to GASCO Physicians, Administrator and Affiliate Members or anyone attending the President’s Reception, the Breakfast for Fellows and New Physicians or Business of Oncology sessions on Saturday or Sunday program on Patient Navigation. To help us plan for classroom and food functions I am attending (check all that apply):
Friday Evening GASCO President’s Reception Saturday am Breakfast for Fellows and New Physicians (Less than 2 years in practice) Full Saturday Business of Oncology Program and Meals - including breakout session Full Sunday Patient Navigator Program and Meals – including breakout session
You may register by regular mail, fax (770) 951-2157, or register online at www.gasco.us. The registration
deadline is July 17, 2009.
Georgia Society of Clinical Oncology
3330 Cumberland Boulevard, Suite 225 Atlanta, Georgia 30339
For questions contact Kellie Reich ([email protected]),
(770) 951-1018 or Toll Free (877) 88 GASCO
Agenda for GASCO Annual Meeting July 24th - 26th, 2009
Hyatt Regency Hotel, Atlanta GA Friday ~ July 24, 2009_ 5:30 – 7:30 PM President’s Reception for GASCO attendees, exhibitors and guests Saturday ~ July 25, 2009 – Program for GASCO Administrators’ Association 8:00 – 8:45 AM Continental Breakfast and Meeting Registration - Exhibit Area 8:00 – 8:45 AM Breakfast for Fellows and New Physicians – “What They Didn’t Teach You in Medical School – The
Business Side of Medical Practice” Russ Still – Executive V.P, Medical Management Associates, Inc.
8:45 – 9:30 AM Best of ASCO (BOA) Breakouts on Clinical Issues & GASCO Business of Oncology Sessions -
Employment Practices During Difficult Times – 9:30 – 10:00 AM Break 10:00 – 12:00 PM BOA Breakouts and GASCO Business of Oncology & Sessions - RAC Audits, Red Flag Rules
and HIPAA Privacy Updates- Speakers to include representative from CMS and/or RAC Contractor – TBA
12:00 – 12:45 PM Lunch & Roundtable Session 12:45 – 2:15 PM BOA Breakouts and GASCO Business of Oncology
Oncology Coding Updates – Bobbi Buell Sunday ~ July 26, 2009 – Special Seminar – Promoting Cancer Patient Navigation in Georgia 8:00 – 9:00 AM Continental Breakfast and Meeting Registration
Buffet in the Exhibit Hall – Exhibits Open 9:00 – 9:10 AM Welcome and Opening Remarks
Matthew Mumber, M.D., President, Georgia Society of Clinical Oncology 9:10 – 10:45 AM Keynote Presentation – Q&A - Harold Freeman, M.D.,
Founder Harold P. Freeman Institute for Patient Navigation, Harlem, N.Y. 10:45 – 11:00 AM Break 11:00 – 12:00 PM Evolving Roles in Cancer Patient Navigation
Caroline Huffman, LCSW, M.Ed. Director of Patient Navigation Services Lance Armstrong Foundation
12:00 – 12:45 PM Lunch & Exhibits (Break into groups for lunch) 12:45 – 2:00 PM Moderated work session on creating a Patient Navigator Association in Georgia
***The American Society of Clinical Oncology designates this educational activity for a maximum of 12.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
2009 Best of ASCO® Atlanta -
Program Agenda Friday – July 24, 2009
Exhibit Hall Open 7:00 AM – 3:30 PM Continental Breakfast Provided 7:00 AM – 8:00 AM Welcome and Introductions 8:00 AM Chair: Michael Carducci, MD - The Johns Hopkins University General Session I: Breast Cancer – Local/Regional and Adjuvant Therapy 8:00 AM – 9:00 AM Discussant: Judy Ellen Garber, MD, MPH - Dana-Farber Cancer Institute
• Tjan-Heijnen, V. Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0(i+)) in the sentinel lymph node (SN): results from the MIRROR study. (Abstract # CRA506)
• Hawley, S. Factors associated with bilateral vs. single mastectomy in a diverse, population-based sample of breast cancer patients. (Abstract # 6502)
• Watanabe, T. Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by 4-cycle taxan with 8-cycle taxan as adjuvant therapy for node positive breast cancer -Results of N-SAS-BC02 trial. (Abstract #516)
• Dawood, S. Adjuvant radiation therapy benefits breast cancer patients with 1 to 3 positive lymph nodes undergoing a modified radical mastectomy and systemic therapy. (Abstract #507)
• Esserman, L. Breast cancer molecular profiles predict tumor response of neoadjuvant Doxorubicin and Taxol, the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). (Abstract #LBA515)
General Session II: Breast Cancer – Metastatic 9:00 AM – 9:30 AM Discussant: Ruth O'Regan, MD - Emory University
• Seidman, A. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). (Abstract #1000)
• Robert, N. RIBBON-1: Randomized, double-blind, placebo-controlled, Phase III trial of chemotherapy with or without bevacizumab (B) for 1st-line treatment of HER2-negative locally-recurrent or metastatic breast cancer (MBC). (Abstract #1005)
• Vogel, C. A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): final results. (Abstract #1017)
***The American Society of Clinical Oncology designates this educational activity for a maximum of 12.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Page 2 General Session III: Breast Cancer – New Drug Therapies 9:30 AM – 10:00 AM Discussant: Lisa A. Carey, MD - University of North Carolina
• O'Shaugnessy, J. Efficacy of BSI-201, a Poly (ADP-ribose) Polymerase-1 (PARP1) inhibitor, in Combination With Gemcitabine/Carboplatin (G/C) in Patients with Metastatic Triple Negative Breast Cancer (TNBC): Results of a Randomized Phase 2 Trial. (Abstract #3)
• Tutt, A. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. (Abstract #CRA501)
• Audeh, M. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. (Abstract #5500)
Break 10:00 AM – 10:15 AM General Session IV: Developmental Therapeutics and Pathways 10:15 AM – 11:00 AM Discussant: Elisabeth I. Heath, MD - Karmanos Cancer Institute
• Tolcher, A. A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). (Abstract #3503)
• Adjei, A. Results of a Phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies. (Abstract #3511)
• Kwak, E. Clinical Activity Observed in a phase 1 dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. (Abstract #3509)
General Session V: Genitourinary Cancers 11:00 AM – 12:00 PM Discussant: Daniel J. George, MD - Duke Medical Center
• Rini, B. Bevacizumab plus Interferon-alpha versus Interferon-alpha Monotherapy in Patients with Metastatic Renal Cell Carcinoma: Results of Overall Survival for CALGB 90206. (Abstract #LBA5019)
• Escudier, B. Final results of the phase III, randomised, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-?2a (IFN) in metastatic renal cell carcinoma (mRCC). (Abstract #5020)
• Sternberg, C. A randomized, double-blind phase III study of Pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). (Abstract #5021)
• Scher, H. Antitumor activity of MDV3100 in a Phase 1-2 study of Castration-Resistant Prostate Cancer (CRPC). (Abstract #5011)
Boxed Lunches Provided 12:00 PM – 1:00 PM
***The American Society of Clinical Oncology designates this educational activity for a maximum of 12.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Page 3 General Session VI: General Oncology and Patient Care 1:00 PM – 1:30 PM Discussant: Douglas W. Blayney, MD - University of Michigan
• Mueller, R. Adjuvant whole brain radiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastases - results of the EORTC 22952-26001 study. (Abstract #2008)
• Mujahid, M. Racial/ethnic differences in treatment delay in a multi-ethnic sample of women with breast cancer. (Abstract #6503)
• Quinn, G. National survey of physicians practice patterns: fertility preservation and cancer patients. (Abstract #CRA9508)
General Session VII: Lymphoma 1:30 PM – 2:30 PM Discussant: Hanna Jean Khoury, MD, FACP - Emory University
• Schuster, S. Idiotype vaccine therapy (BiovaxID™) in follicular lymphoma in first complete remission: phase III clinical trial results (Abstract #2)
• Cunningham, D. A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin's lymphoma.(Abstract #8506)
• Gisselbrecht, C. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. (Abstract #8509)
• Bartlett, N. Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase 1 dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). (Abstract #8500)
General Session VIII: Leukemia and Myeloma 2:30 PM – 3:00 PM Discussant: Nikhil C. Munshi, MD - Dana-Farber Cancer Institute
• Fernandez, H. A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900. (Abstract #7003)
• Palumbo, A. A Phase III Study of VMPT versus VMP in newly diagnosed elderly myeloma patients. (Abstract #8515)
Break 3:00 PM – 3:15 PM
***The American Society of Clinical Oncology designates this educational activity for a maximum of 12.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Page 4 General Session IX: Head and Neck Cancers 3:15 PM – 4:00 PM Discussant: David J. Adelstein, MD - Cleveland Clinic
• Hitt, R. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin /5-FU (PF) or docetaxel/cisplatin/5-FU (TPF) follow by chemoradiotherapy (CRT) versus (CRT) alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). (Abstract #6009)
• Overgaard, J. Randomized study of Aranesp as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - Final outcome of the DAHANCA 10 trial. (Abstract #6007)
• Gillison, M. Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. (Abstract #6003)
General Session X: Gastrointestinal Cancers – Colorectal/Liver 4:00 PM – 5:00 PM Discussant: Joel Picus, MD - Washington University
• Gerard, J. Randomized multicenter phase III trial comparing two neoadjuvant chemo-radiotherapy (CT-RT) regimens (RT45-Cap vs RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC). Results of the ACCORD 12/0405 PRODIGE 2. (Abstract #LBA4007)
• Wolmark, N. A phase III trial comparing mFolfox6 to mFolfox6 + bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. (Abstract #LBA4)
• Tejpar, S. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan ( PETACC 3 - EORTC 40993 - SAKK 60/00 trial). (Abstract #4001)
• Aschele, C. Preoperative fluorouracil (FU)-based chemoradiation +/- weekly oxaliplatin in locally advanced rectal cancer. Pathologic response analysis of the STAR (Studio Terapia Adiuvante Retto)-01 randomized phase III trial. (Abstract #CRA4008)
Saturday, July 25, 2009
Continental Breakfast Provided 7:30 AM – 8:00 AM General Session XI: Gastrointestinal Cancers – Non-Colorectal (Gastric and Anal Cancers) 8:00 AM – 8:45 AM Discussant: Jimmy J. Hwang, MD - Georgetown University Hospital
• Van Cutsem, E. Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). (Abstract #LBA4509)
• Schuhmacher, C. Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC Phase III Trial # 40954. (Abstract #4510)
• James, R. A randomised trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II). (Abstract #LBA4009)
***The American Society of Clinical Oncology designates this educational activity for a maximum of 12.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Page 5 General Session XII: Gastrointestinal Cancers – Non-Colorectal (Pancreas/Hebatobiliary Tract) 8:45 AM – 9:30 AM Discussant: Daniel Laheru, MD - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Riess, H. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC). Results of the CONKO 004 trial. (Abstract #LBA4506)
• Valle, J. Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): results of a multicentre, randomised phase III trial (the UK ABC-02 trial). (Abstract #4503)
• Arnold, R. Placebo-controlled, double-blind, prospective, randomized study of the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. (Abstract #4508)
• Neoptolemos, J. ESPAC-3(v2) - A multicentre, international, open label, randomised controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. (Abstract #LBA4505)
Break 9:30 AM – 10:00 AM General Session XIII: Gynecologic Cancers 10:00 AM – 11:00 AM Discussant: Ursula Matulonis, MD - Dana-Farber Cancer Institute
• Pignata, S. Carboplatin plus paclitaxel versus carboplatin plus stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): final results of the MITO-2 randomized multicenter trial. (Abstract #LBA5508)
• Pujade-Lauraine, E. CALYPSO phase III study: comparison of carboplatin (C) pegylated liposomal doxorubicin (PLD) (C-D) and carboplatin-paclitaxel (C-P) in relapsed platinum-sensitive ovarian cancer (OC) by the Gynecologic Cancer Intergroup (GCIG). (Abstract #LBA5509)
• Herrstedt, J. A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102):gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): survival of FIGO stage I-IIA patients. (Abstract #LBA5510)
• Rustin, G. A randomised trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). (Abstract #1)
• Dueñas-González, A. A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix. (Abstract #CRA5507)
***The American Society of Clinical Oncology designates this educational activity for a maximum of 12.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Page 6 General Session XIV: Survivorship and Supportive Care 11:00 AM – 12:00 PM Discussant: Barbara A. Murphy, MD - Vanderbilt University
• Nathan, P. Cancer screening in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). (Abstract #CRA6501)
• Stuber, M. Prevalence and predictors of Posttraumatic Stress Disorder in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. (Abstract #CRA10002)
• Kunitake, H. Routine preventive care and cancer surveillance in long-term survivors (LTS) of colorectal cancer: Results from NSABP Protocol LTS-01. (Abstract #6500)
• Ryan, J. Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients. (Abstract #9511)
• Jean- Pierre, P. Neuroprotective effect of SSRI among 781 cancer patients receiving chemotherapy: A URCC CCOP Study. (Abstract #9512)
Boxed Lunches Provided 12:00 PM – 12:45 PM General Session XV: Lung Cancer 12:45 PM – 2:00 PM Discussant: Fadlo Raja Khuri, MD - Emory Winship Cancer Institute
• Felip, E. Surgery (S) alone, or preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) PC chemotherapy in early-stage non-small cell lung cancer (NSCLC): Results of the NATCH multicenter, randomized, phase III trial. (Abstract #7500)
• Fouret, P. MSH2 and adjuvant cisplatin-based chemotherapy in non-small-cell lung cancer. (Abstract #CRA7502)
• Chlebowski, R. Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the women's health initiative randomized clinical trial. (Abstract #CRA1500)
• Cappuzzo, F. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following non-progression with 1st-line platinum-based chemotherapy in patients with advanced NSCLC. (Abstract #8001)
• Miller, V. A randomized, double blind, placebo controlled, Phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for 1st-line treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). (Abstract #LBA8002)
• Belani, C. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). (Abstract #CRA8000)
• O'Byrne, K. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study. (Abstract #8007)
Adjourn 2:00 PM
Hotel Information
265 Peachtree Street, NE Atlanta, GA 30303 If booking directly ASK FOR THE ASCO RATE (we are sharing the room block) Hotel Front Desk: (800) 233 1234 Room Rates: Single/Double/Other ~ $190/Night Call GASCO at (770) 951-1018 if you encounter any problems reserving a room.
Maps & Directions
Hotel Address Hyatt Regency Atlanta 265 Peachtree Street NE, Atlanta, Georgia, USA 30303 Tel: (800) 233-1234 Directions When traveling northbound on 75/85, driving from Hartsfield-Jackson International Airport (12 miles), or traveling on Interstate 20 west and eastbound: Take 75/85 North, take the right-hand exit 248-C (International Blvd.). Turn left onto International Blvd. Turn right at the third traffic light onto Peachtree Center Avenue. Hyatt Regency Atlanta's Motor Lobby entrance is one block on the left. When traveling southbound on 75/85, and traveling from GA 400: Exit 249-C (Williams Street). Go straight off exit. At the fourth traffic light, turn left onto Harris Street. Then take the third left onto Peachtree Center Avenue. Hyatt Regency Atlanta's Motor Lobby entrance is on the left. When Traveling via MARTA from the Airport: Take the northbound train to the Peachtree Center Station stop, one stop north of the Five Points transfer station. Exit the train and take the escalator up towards Peachtree Center Mall. Once inside the mall, follow the signs to the covered walkway into the hotel.
